Apheresis Market Forecast Report | Share, Size & Outlook 2030

[Research Report] The global apheresis market was valued at US$ 3,133.05 million in 2022, and the apheresis market size is projected to reach US$ 5,235.00 million by 2031. It is expected to register a CAGR of 8.29% in the forecast period.

Market Insights and Analyst View:

Apheresis, or pheresis, is a medical procedure that involves separating and extracting specific blood components from a donor or patient. This therapeutic intervention utilizes a specialized machine called an apheresis machine, which can selectively collect particular blood components while returning the remainder of the blood to the individual. Depending on the targeted medical indication, the process typically involves removing, isolating, and returning specific blood constituents, such as plasma, platelets, red blood cells, or white blood cells. Apheresis is critical in treating various medical conditions, including autoimmune disorders, hematological malignancies, and certain neurological diseases. This procedure enables healthcare practitioners to manipulate an individual's blood components therapeutically, addressing certain disease states or harvesting specific blood constituents for therapeutic use in others.

Growth Drivers and Opportunities:

The primary drivers of the apheresis market's growth are the ongoing technological advancements in developing new techniques, which have significantly expanded the scope and sophistication of this therapeutic procedure, offering enhanced precision and therapeutic potential. Modern innovations have led to the evolution of more targeted and efficient apheresis methodologies, facilitating the selective extraction, modulation, and reinfusion of specific blood constituents with heightened accuracy and reduced invasiveness. These advancements have paved the way for the customization of apheresis procedures, enabling tailored treatment regimens for diverse medical indications. Furthermore, technological progress has given rise to integrating automated apheresis systems equipped with advanced software, real-time monitoring capabilities, and improved biocompatibility, enhancing safety, procedural efficiency, and patient comfort. The development of novel apheresis techniques, including selective immune modulation and cellular engineering strategies, exemplifies the transformative impact of technological advancements in expanding the therapeutic repertoire of apheresis, offering promising avenues for personalized medicine and targeted disease intervention. As a result, these technological strides are poised to elevate the clinical utility and impact of apheresis across a broad spectrum of medical specialties, underscoring its pivotal role in addressing complex disease states and advancing the frontiers of therapeutic hemapheresis.

On the other hand, the shortage of skilled professionals presents a significant challenge hindering the growth of the apheresis market. Apheresis procedures require specialized expertise in operating apheresis machines, meticulous patient monitoring, and a comprehensive understanding of each procedure's therapeutic goals. The scarcity of trained professionals adept in performing apheresis techniques can result in limited accessibility to these critical procedures, potentially impeding the timely and optimal delivery of apheresis-based therapies. Addressing this limitation necessitates strategic investments in training programs, educational initiatives, and professional development efforts to cultivate a proficient workforce capable of meeting the escalating demand for apheresis services. By mitigating the shortage of skilled professionals in the apheresis domain, the healthcare industry can effectively bolster the capacity to deliver high-quality, specialized treatments, thereby fostering the sustained advancement and expansion of the apheresis market.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Apheresis Market: Strategic Insights

Apheresis Market

• Market Size 2023
  US$ 3.39 Billion
• Market Size 2031
  US$ 6.42 Billion

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Product

• Devices and Disposables

Apheresis Procedure

• Leukapheresis
• Plasmapheresis
• Plateletpheresis
• Erythrocytapheresis
• Other Apheresis Procedures

Technology

• Centrifugation and Membrane Separation

Application

• Renal Disorders
• Hematological Disorders
• Neurological Disorders
• Autoimmune Disorders
• Other Applications

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope:

The “Global apheresis market” is segmented based on the product, apheresis procedure, technology, application, and region. The apheresis market is broadly segmented into devices and disposables. The apheresis market is classified based on procedures, such as leukapheresis, plasmapheresis, plateletpheresis, erythrocytapheresis, and others. The technology segment of the apheresis market is broadly segmented into centrifugation and membrane separation. Based on application, the market is classified into renal disorders, hematological disorders, neurological disorders, autoimmune disorders, and other applications. The apheresis market based on geography is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America)

Segmental Analysis:

Based on the application, the apheresis market is segmented into renal disorders, hematological disorders, neurological disorders, autoimmune disorders, and other applications. In 2022, the apheresis market revenue was mostly attributed to hematological disorders, which had the largest share. Hematologic disorders refer to conditions affecting blood and organs that create blood, such as issues with platelets, white blood cells, red blood cells, bone marrow, lymph nodes, and the spleen. Worldwide, hematological illnesses have a significant impact on people's morbidity and mortality. About 100,000 Americans have sickle cell disease (SCD), according to the CDC's May 2022 update. About one in every 365 Black or African American births experience it. Early detection and therapy are the greatest strategies to preserve a patient's life if they have a blood cell problem. Therefore, the studied segment is anticipated to increase throughout the forecast period due to the rising burden of hematological occurrences and expanding applications of apheresis as a therapy strategy for hematological disorders.

The apheresis market is segmented into disposable apheresis kits and devices based on the product segment. Due to significant advancements in the production of blood bags, disposable kits, and tubing, the disposable apheresis kit category is expected to continue its dominant position in the market, holding a share of about 73% in 2022 and continuing to do so throughout the forecast period. The segment is growing due to rising demand for automated component separation processes, particularly in developed economies.

Based on procedure, the apheresis market is classified into leukapheresis, plasmapheresis, plateletpheresis, erythrocyte apheresis, and other apheresis procedures. Patients with compromised immune systems are given plasma-based drugs to increase their resistance to infection and disease. The market is anticipated to expand with the growth in blood-related illnesses and the increasing need for treatments generated from plasma. White blood cells (WBC) are extracted from the blood drained from the body using plasmapheresis. Treatment for graft-versus-host disease (GvHD) and T-cell lymphoma (CTCL) requires this kind of surgery, which is anticipated to increase demand for plasmapheresis.

Based on the technology segment, the apheresis market is segmented into centrifugation and membrane separation. Centrifugation produces results more quickly, easily, and precisely than membrane filtering; it is used more frequently. The market is also anticipated to increase due to the rising demand for automated apheresis systems. To increase the efficiency of their products, businesses are developing automated and highly modern technical gadgets. The manufacturers are developing an automated interface system, a customized anticoagulant infusion system, and automatic apheresis equipment with continuous flow centrifugation.

Regional Analysis:

Based on geography, the global apheresis market is divided into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Due to the rising prevalence of blood-related illnesses like kidney disease, metabolic diseases, cancer, and neurological disorders, as well as the region's well-established healthcare system and high patient awareness, North America is predicted to increase throughout the forecast period. In the United States, a person is diagnosed with blood cancer roughly every three minutes, according to the Leukemia & Lymphoma Society (LLS) 2021. Leukemia, lymphoma, and myeloma cases made up 9.8% of the 1,898,160 new cases of cancer that were diagnosed in the US in 2021. The market under study is expanding due to the rising prevalence of the target disorders.

The demand for apheresis is rising due to the nation's expanding reimbursement regulations for operations and equipment. The UnitedHealthcare Commercial Medica Policy, published in January 2022 by United Healthcare Group, offers a medical policy for apheresis procedures for various indications, except stem cell harvesting or collection for bone marrow/stem cell transplantation. The country's market for apheresis is ultimately driven by the policies now in place for the procedures, which are raising demand for the treatments among the target demographic.

In addition, Apheresis Awareness Day was proclaimed by the American Society for Apheresis (ASFA) on September 21, 2021, and it will subsequently be observed on the third Tuesday in September each year. Using evidence-based practice to advance apheresis medicine and increase awareness was meant to honor the many donors, patients, and apheresis practitioners who have committed their lives to save others. Therefore, during the forecast period, these previously mentioned variables are anticipated to enhance the apheresis market in North America greatly.

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the global apheresis market are listed below:

1. In September 2023, The FDA approved APHEXDA (motixafortide) and filgrastim (G-CSF) by BioLineRx Ltd. to mobilize hematopoietic stem cells in peripheral blood for patients with multiple myeloma. The stem cells will be collected and then autologously transplanted. Subcutaneous usage of APHEXDA is achieved through injectable administration.
2. In July 2022, Eliaz Therapeutics and Terumo Blood and Cell Technologies worked together to develop and market a unique therapeutic apheresis treatment for acute kidney damage (AKI).
3. In June 2022, Using the company's Spectra Optia Apheresis System, an automated red blood cell exchange (RBCX) procedure was chosen by NHS England to treat sickle cell disease. Terumo Blood and Cell Technologies is a medical technology company specializing in products, software, and services for blood component collection, therapeutic apheresis, and cellular technologies. This decision will lead to a wider implementation of Spectra Optia in hospitals throughout England. Patients with sickle cell illness will now have better access to this game-changing medication.
4. In October 2021, The US FDA granted Haemonetics 510(k) certification for their Persona-enabled NexSys PCS system.

Competitive Landscape and Key Companies:

Some of the prominent players operating in the global apheresis market are Asahi Kasei Corporation, B. Braun SE, Fresenius SE & Co. KGAA (Fresenius Kabi AG), Haemonetics Corporation, Terumo Corporation (Terumo BCT Inc.), Kaneka Corporation, Sumitomo Bakelite Company Limited (Kawasumi Laboratories Inc.), Medica SPA, Baxter International, Cerus Corporation, Macopharma SA, Otsuka Holdings Co. Ltd (JIMRO Co. Ltd) and amongst others. These apheresis markets focus on new product launches and geographical expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, allowing them to serve many customers and subsequently increase their market share. The report offers apheresis market trends analysis emphasizing various parameters such as technological advancements, market dynamics, and competitive landscape analysis of leading global market players.

Apheresis Market Report Scope